CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Search
Taking cancer on together
Through their work, our colleagues from around the world hope to empower patients to Take Cancer On.
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Translational Medicine in Immunology
Find out how translational medicine is helping bring transformational therapies to patients
BI 764532: DLL3/CD3 T-cell engager
BI 764532: DLL3/CD3 T-cell engager
Samina Ajaz Hussain
Discover how Samina never looked back on her career move to Patient Safety.
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® Cancer Vaccine
KISIMA® Cancer Vaccine
CD137/FAP agonist
CD137/FAP agonist
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Expert insights: the top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
VSV-GP
VSV-GP
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Introducing CIAS
Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment